Beximco Pharmaceuticals (BXP) investor relations material

Executive summary

• Net revenue for July–December 2024 rose to Tk 24,013 million (consolidated), up 8.8% year-over-year; standalone revenue reached Tk 19,952 million, up 8.9%.

• Consolidated net profit after tax increased 17.5% year-over-year to Tk 3,535 million; standalone net profit rose 18.1% to Tk 3,421 million.

• Earnings per share (EPS) improved to Tk 7.87 (consolidated) and Tk 7.67 (standalone), compared to Tk 6.69 and Tk 6.49, respectively, in the prior year.

Financial highlights

• Consolidated gross profit margin was 45.7%, up from 44.4% year-over-year; standalone gross margin was 45.5%.

• Operating profit (consolidated) increased 12% to Tk 5,088 million; standalone operating profit rose 13.5% to Tk 4,539 million.

• Net asset value (NAV) per share reached Tk 111.35 (consolidated) and Tk 109.90 (standalone), up from Tk 101.11 and Tk 100.15, respectively.

• Net operating cash flow per share declined to Tk 6.13 (consolidated) and Tk 5.34 (standalone), compared to Tk 10.01 and Tk 9.54 in the prior year.

Outlook and guidance

• Management notes operating cash flow per share declined due to higher working capital needs, mainly from strategic inventory buildup.

• No forward-looking revenue or profit guidance provided; focus remains on domestic and international market expansion.